Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson’s Disease

Abstract

Models could be improved by a larger cohort and by addition of other types of Parkinson's disease biomarkers to the analysis.